


Chemical proteomics in drug design




Roman Zubarev

Chemistry I, MBB, Biomedicum, Karolinska Institutet, Stockholm, Sweden

Roman.Zubarev@ki.se




New Medicines Needed for Those Who Do Not Respond to Current Therapy




Source: Spear B, et. al. *Trends in Molecular Medicine*, 7(5):201-204, 2001; Eli Lilly internal documents.

Proteins as drug targets



Santos *et al.* *Nature Reviews Drug Discovery* (2016)

Proteins by function



Chemical space is vast – millions of drugs are yet to be discovered



10^{63}

Drug-like small molecules in chemical space

10^{24}



Stars in the universe

10^{20}


Potential compounds in Merck KGaA's Merck Accessible Inventory (MASSIV)

10^4

Small-molecule drugs



Most small-molecule drugs bind to protein target



<https://www.medgadget.com/2013/07/new-technology-allows-for-monitoring-of-drug-target-binding-in-cells-and-tissues.html>

Are drugs 'silver bullets' ?...

MAY 28, 2001 www.time.com AOL Keyword: TIME


TIME

THERE IS NEW **AMMUNITION**
IN THE WAR AGAINST
CANCER.
THESE ARE THE BULLETS.

Revolutionary new pills like **GLEEVEC** combat cancer by targeting only the diseased cells. Is this the breakthrough we've been waiting for?




Imatinib (Gleevec)




Inhibits Tyr kinase BCR-Abl



Drugs are usually not very specific





- **Tykerb** – Breast cancer
- **Gleevac** – Leukemia, GI cancers
- **Nexavar** – Kidney and liver cancer
- **Staurosporine** – natural product – antifungal and antihypertensive alkaloid




Chemical Proteomics Aims

- Target discovery
- Target engagement
- Thermal profiling
- Redox analysis
- Deuterium exchange analysis




New drug


No Chemistry!




Mechanism of action







Changes in redox state



Mechanism of death



Bottom-Up (Shotgun) Proteomics




M N I F E M L R I D E G L R L K I Y K D T E G Y Y T I G I G
 H L L T K S P S L N A A K S E L D K A I G R N N G V I T K
 D E A E K L F N Q D V D A A V R G I L R N A K L K P V Y D S
 L D A V R R A L I N M V F Q M G E T G V A G F T N S L R M
 L Q Q K R W D E A A N L A K S R W Y N Q T P N R A K R V I
 T T F R T G T W D A Y K N L

<https://prosightptm.scs.uiuc.edu/>

Peptide ID; Protein ID
Some modifications

Quantitative Proteomics






Research Article

OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification[†]


Max Bylesjö, Mattias Rantalainen, Olivier Cloarec, Jeremy K. Nicholson, Elaine Holmes, Johan Trygg

OPLS-DA - Orthogonal [Projection to Latent Structures / Partial Least Square] – Discriminant Analysis




Chemical Proteomics workflow


Saei, A. et al., *Redox Biology*, 2020,
doi.org/10.1016/j.redox.2020.101491




Functional Identification of Targets by Expression Proteomics, FITExP



Protein abundance change: DHFR




Protein abundance change: TOPI




Functional Identification of Targets by Expression Proteomics, FITExP


OPLS-DA - Orthogonal [Projection to Latent Structures / Partial Least Square] – Discriminant Analysis



ProTargetMiner: Target and mechanism deconvolution






ProTargetMiner: Target and mechanism deconvolution



Saei, A. et al., *Nat. Commun.* 2019, 10, Article number: 5715.




Hierarchical clustering

≈300 LC-MS/MS runs
7572 proteins quantified
4557 best-quantified proteins used for mapping



PCA: 13 dimensions (1% cut-off)


FITeXP: Functional Identification of Target by Expression Proteomics



Challenges of Single Cell Proteomics

- Size = 5-10 μm
- Protein amount = 100-250 pg



Can we take
Chemical Proteomics
to Single Cell level?...



Dynamic range of proteins in the
cell:
 ≥ 7 orders of magnitude


Finding the protein in the right context at the time remains an important obstacle to overcome!

SCoPE-MS enables Single Cell Proteomics



Vegvari et al., *Anal. Chem.* 2022, 94(26):9261-9

96 A549 cells treated with MTX vs 96 untreated cells






Dihydrofolate reductase

Vegvari et al., *Anal. Chem.* 2022, 94(26):9261-9

Protein Abundance

vs


Protein Solubility



https://commons.wikimedia.org/wiki/File:PaxDB_C8ORF48_Protein_Abundance.png

Vendruscolo lab, Cambridge University

Protein Aggregation



Adopted from: <https://doi.org/10.1002/cphc.201900904>


Thermal Proteome Profiling (TPP)

Tracking cancer drugs in living cells by thermal profiling of the proteome


SCIENCE

3 OCTOBER 2014 • VOL 346 ISSUE 6205


Mikhail M. Savitski,^{1*} Friedrich B. M. Reinhard,^{1†} Holger Franken,¹ Thilo Werner,¹ Maria Fälth Savitski,¹ Dirk Eberhard,¹ Daniel Martinez Molina,² Rozbeh Jafari,² Rebecca Bakszt Dovega,² Susan Klaeger,^{3,4} Bernhard Kuster,^{3,4} Pär Nordlund,^{2,5} Marcus Bantscheff,^{1*} Gerard Drewes^{1*}






TPP identifies protein interaction partners of proteins added to cell lysates




System-wide Identification of Substrates by Thermal Analysis - SIESTA



Thioredoxin reductase TrxR




TrxR dimer + Trx




Conserved C-terminal sequence Gly-Cys-**SeCys**-Gly

System 1: TXNRD1 + NADPH -> S-S bond reduction



System 1: TXNRD1 + NADPH -> S-S bond reduction

e




f

Validation: redox proteomics

■ NADPH


■ TXNRD1+NADPH

■ TXNRD1




A. Saei et al., *Nat. Commun.* 2021

Redox proteomics




TPP limitations



- Not all proteins aggregate with temperature
- Too time consuming to measure every temperature point

Proteome Integral Solubility Alteration (PISA) Assay



1D PISA


$N_{HT} \approx 10$

2D PISA

$N_{HT} \approx 100$


Gaetani M, et al. *J Proteome Res* 2019,
DOI:10.1021/acs.jproteome.9b00500

- Drug binding is not the only parameter of interest;
Residence time of drug on target is of very high significance




PISA determines drug residence time


Removal of the drug by filtration



Time-series PISA analysis and LC-MS/MS measurement




Measurement of drug residence time



PISA determines drug residence time


b

kinase inhibitor ponatinib




PISA helps ranking targets

a




Prioritization of targets




c

	Rank ΔSm	Rank ΔSm	Rank conc-PISA and conc-PISA and cResT-PISA and cResT-PISA
1	LYN	1 MAPK14	1 LYN
2	MAPK14	2 CSK	2 RIPK1
3	CSK	3 LYN	3 CSK
4	RIPK2	4 RIPK1	4 MAPK14
5	IRAK4	5 TNIK	5 RIPK2
6	TNIK	6 BRAF	6 IRAK4
7	BRAF	7 DCK	7 TNIK
8	RIPK1	8 FECH	8 FECH
9	CDK5	9 CDK5	9 BRAF
10	DCK	10 IRAK4	10 CDK5
11	FECH	11 RIPK2	11 DCK


b



d




TPP/PISA limitations



- Not all proteins aggregate with temperature
- Too time consuming to measure every temperature point


Protein Aggregation








Adopted from: <https://doi.org/10.1002/cphc.201900904>

Ion-Based Proteome-Integrated Solubility Alteration Assays for Systemwide Profiling of Protein–Molecule Interactions

Christian M. Beusch, Pierre Sabatier, and Roman A. Zubarev*



iPISA works in lysate and cells



C. Beusch et al., *Analyt Chem* 2022

Conclusions:

- Chemical proteomics reveals drug targets without chemical modification of drugs
- FITExP / ProTargetMiner uses expression level changes for drug target deconvolution; is already translated to single cell level
- TPP/PISA performs target deconvolution based on solubility changes
- PISA allows one to easily determine:
 - interacting partners of proteins;
 - enzyme substrates;
 - the residence time of drugs
- Ion-based PISA reaches sub-microgram level of sensitivity

Acknowledgements


Kim Haselmann
Bogdan Budnik
Frank Kjeldsen
Michael Lund Nielsen
Jesper Olsen
Igor Ivonin
Oleg Silivra
Christopher Adams
Alexander Misharin
Mikhail Savitski
Thomas Köcher
Corina Mayrhofer
Y.M. Eva Fung
Konstantin Artemenko
Therése Hemström
Pierre Le Grevès
Atim Enyenihi
David Good
Ernesto Gonzales
Consuelo Marin Vicente
Marta Guerrero Valero
Constantin Chingin
Yaroslav Lyutvinskiy
Aleksandr Manoilov
Hongqian Yang
Piliang Hao
Mohammad Pirmoradian
Natliya Tarasova
Alexandra Bernadotte
Bo Zhang
Alexey Chernobrovkin
Amirata Saei
Pierre Sabatier
Christain Beusch
Janet Wang



Thorleif Lavold
Juan Astorga-Wells

Alexander Makarov
Yury Tsybin
Dimitris Papanastasiu
Albert Lebedev

ThermoFisher Scientific
Biomotif AB
Swedish Research Council
KAW foundation, VINNOVA
European Union, EuroStars
Cancerfonden



Produced by Pedro Lali